Dr. Marvanyos Ede Laszlo,Virag Attila,dr. Gregor Tamas,Dr. Volk Balazs,Tothne Lauritz Maria Dr.,Dr. Pongo Laszlo,Peregi Balazs,Dr. Lukacs Gyula,Varga Zoltan,Dr. Dancso Andras
申请号：
HU1400264
公开号：
HU231013B1
申请日:
2014.05.26
申请国别(地区):
HU
年份:
2019
代理人:
摘要：
The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.
